TY - JOUR
T1 - Deficiency in coatomer complex I causes aberrant activation of STING signalling
AU - Steiner, Annemarie
AU - Hrovat-Schaale, Katja
AU - Prigione, Ignazia
AU - Yu, Chien Hsiung
AU - Laohamonthonkul, Pawat
AU - Harapas, Cassandra R.
AU - Low, Ronnie Ren Jie
AU - De Nardo, Dominic
AU - Dagley, Laura F.
AU - Mlodzianoski, Michael J.
AU - Rogers, Kelly L.
AU - Zillinger, Thomas
AU - Hartmann, Gunther
AU - Gantier, Michael P.
AU - Gattorno, Marco
AU - Geyer, Matthias
AU - Volpi, Stefano
AU - Davidson, Sophia
AU - Masters, Seth L.
N1 - Funding Information:
This work was supported by: Fellowships from the Australian National Health and Medical Research Council (NHMRC GNT2008699) (S.L.M.), HHMI-Wellcome International Research Scholarship 208694/Z/17/Z (S.L.M.), the Sylvia and Charles Viertel Foundation VTL2016F027 (S.L.M.), the National Health and Medical Research Council Early Career Fellowship (S.D. GNT1143412), the WEHI Centenary Fellowship (C.-H.Y.) and Ormond College’s Thwaites Gutch Fellowship in Physiology (C.-H.Y.), Italian Ministry of Health, Ricerca Corrente (M.Ga.). M,Ge., G.H. and T.Z. received funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – EXC2151 – 390873048 and TRR237 (G.H., T.Z.). A.S. is supported by the University of Melbourne through the International Research Training Program Scholarship and the DFG - GRK 2168. S.L.M. receives funding from Glaxosmithkline and IFM therapeutics. S.V. received financial support from the Italian Ministry of Foreign Affairs/Italian Health Ministry (PGR grant IN17GR10).
Funding Information:
M.Ga. declares consultancy and speakers fee from Novartis and SOBI. S.L.M. receives funding from IFM therapeutics and M.Ge. consults to IFM Therapeutics. The other authors declare no competing interests.
Funding Information:
We thank Thomas Hayman (Melbourne University, WEHI) and Fiona Moghaddas (Melbourne University, WEHI) for kindly providing the single guide RNAs for MAVS and STING, respectively. We thank Cynthia Louis (Melbourne University, WEHI) for providing human IL8 primers. This work was supported by: Fellowships from the Australian National Health and Medical Research Council (NHMRC GNT2008699) (S.L.M.), HHMI-Wellcome International Research Scholarship 208694/Z/17/Z (S.L.M.), the Sylvia and Charles Viertel Foundation VTL2016F027 (S.L.M.), the National Health and Medical Research Council Early Career Fellowship (S.D. GNT1143412), the WEHI Centenary Fellowship (C.-H.Y.) and Ormond College?s Thwaites Gutch Fellowship in Physiology (C.-H.Y.), Italian Ministry of Health, Ricerca Corrente (M.Ga.). M,Ge., G.H. and T.Z. received funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany?s Excellence Strategy ? EXC2151 ? 390873048 and TRR237 (G.H., T.Z.). A.S. is supported by the University of Melbourne through the International Research Training Program Scholarship and the DFG - GRK 2168. S.L.M. receives funding from Glaxosmithkline and IFM therapeutics. S.V. received financial support from the Italian Ministry of Foreign Affairs/Italian Health Ministry (PGR grant IN17GR10).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4/28
Y1 - 2022/4/28
N2 - Coatomer complex I (COPI) mediates retrograde vesicular trafficking from Golgi to the endoplasmic reticulum (ER) and within Golgi compartments. Deficiency in subunit alpha causes COPA syndrome and is associated with type I IFN signalling, although the upstream innate immune sensor involved was unknown. Using in vitro models we find aberrant activation of the STING pathway due to deficient retrograde but probably not intra-Golgi transport. Further we find the upstream cytosolic DNA sensor cGAS as essentially required to drive type I IFN signalling. Genetic deletion of COPI subunits COPG1 or COPD similarly induces type I IFN activation in vitro, which suggests that inflammatory diseases associated with mutations in other COPI subunit genes may exist. Finally, we demonstrate that inflammation in COPA syndrome patient peripheral blood mononuclear cells and COPI-deficient cell lines is ameliorated by treatment with the small molecule STING inhibitor H-151, suggesting targeted inhibition of the cGAS/STING pathway as a promising therapeutic approach.
AB - Coatomer complex I (COPI) mediates retrograde vesicular trafficking from Golgi to the endoplasmic reticulum (ER) and within Golgi compartments. Deficiency in subunit alpha causes COPA syndrome and is associated with type I IFN signalling, although the upstream innate immune sensor involved was unknown. Using in vitro models we find aberrant activation of the STING pathway due to deficient retrograde but probably not intra-Golgi transport. Further we find the upstream cytosolic DNA sensor cGAS as essentially required to drive type I IFN signalling. Genetic deletion of COPI subunits COPG1 or COPD similarly induces type I IFN activation in vitro, which suggests that inflammatory diseases associated with mutations in other COPI subunit genes may exist. Finally, we demonstrate that inflammation in COPA syndrome patient peripheral blood mononuclear cells and COPI-deficient cell lines is ameliorated by treatment with the small molecule STING inhibitor H-151, suggesting targeted inhibition of the cGAS/STING pathway as a promising therapeutic approach.
UR - http://www.scopus.com/inward/record.url?scp=85128968796&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-29946-6
DO - 10.1038/s41467-022-29946-6
M3 - Article
C2 - 35484149
AN - SCOPUS:85128968796
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 2321
ER -